Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $16.37 USD
Change Today -0.37 / -2.21%
Volume 150.8K
OSIR On Other Exchanges
Symbol
Exchange
NASDAQ GM
Berlin
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

7015 Albert Einstein Drive

Columbia, MD 21046

United States

Phone: 443-545-1800

Fax: 443-545-1701

Osiris Therapeutics, Inc., a stem cell company, focuses on developing and marketing products to treat serious medical conditions in wound, orthopedic, and sports medicine markets. The company’s Biosurgery products, including Grafix, Ovation, Cartiform, and OvationOS, each of which it developed and manufacture. Grafix is a three-dimensional placental tissue matrix for use as a wound covering for application directly to acute and chronic wounds, including diabetic foot ulcers, venous leg ulcers, and burns. OvationOS, a viable bone matrix, is the company’s newest product to be used for bone repair and regeneration. OvationOS is a functionally complete alternative to autograft, the gold standard in bone regeneration. The company markets and distributes Grafix directly to hospitals, clinics and physician offices primarily through its direct sales organization and with limited marketing through agents and distributors. The company distributes Cartiform and OvationOS. It markets its products directly to hospitals and through selected specialty distributors. A significant market for Grafix is chronic wounds, which are primarily treated in the outpatient setting. Strategy The three pillars of the company’s business strategy are to continue its history of innovation, bring about transformation, and to ensure differentiation of its company. Dispositions In 2013, the company sold its Therapeutics business to a wholly-owned subsidiary of Mesoblast Limited. Significant Events In December 2014, Osiris Therapeutics said it has entered into an exclusive, worldwide partnership with Stryker Corporation for the commercialization and development of OSIR's viable bone matrix tissue form. The agreement provides SYK with exclusive, worldwide rights to OSIR's viable bone matrix under the name BIO4. Regulations Grafix, OvationOS, and Cartiform are regulated by the United States Food and Drug Administration (FDA) under 21 CFR Part 1271 Part 361 of the Public Health Service Act, Human Cells, Tissues and Cellular and Tissue-based Products. The company is registered with the FDA as a tissue establishment and is accredited by the American Association of Tissue Banks. History Osiris Therapeutics, Inc. was founded in 1992 as a Delaware corporation. The company reincorporated as a Maryland corporation in 2010.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OSIR:US $16.37 USD -0.37

OSIR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioTime Inc $5.22 USD -0.21
Mesoblast Ltd A$3.79 AUD -0.04
Ocata Therapeutics Inc $6.98 USD -0.02
Organovo Holdings Inc $4.56 USD -0.16
Vitrolife AB kr155.00 SEK 0.00
View Industry Companies
 

Industry Analysis

OSIR

Industry Average

Valuation OSIR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.4x
Price/Book 6.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OSIRIS THERAPEUTICS INC, please visit www.osiristx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.